GRAFT PATCH FOR THE TREATMENT OF MYOPIA AND OPHTHALMIC CONDITIONS

Abstract

The invention provides a synthetic ophthalmic device comprising a porous polymeric structure; wherein said structure is in the shape of a truncated hemisphere and uses thereof in the treatment of ophthalmic conditions, diseases and syndromes.

Claims

1. A synthetic ophthalmic device comprising a porous polymeric structure; wherein said structure is in the shape of a truncated hemisphere having a first top circular opening with a first radius and a hemisphere bottom opening with a second radius and a hemisphere height defined between the centers of said first and second openings; and wherein said porous polymer has pores of less than 5 microns.

2. A synthetic ophthalmic according to claim 1, device having a porous polymeric structure with pores of between 100 nanometers to 5 micrometers.

3. A synthetic ophthalmic device according to claim 1, having a porous polymeric structure with pores of between 5 to 20 microns.

4. (canceled)

5. A synthetic ophthalmic device according to claim 1, being a non-degradable biocompatible patch.

6. A synthetic ophthalmic device according to claim 1, being a biodegradable biocompatible patch.

7. A synthetic ophthalmic device according to claim 1, having a thickness of between 50 to 250 microns.

8. A synthetic ophthalmic device according to claim 1, having a thickness of between 250 to 500 microns.

9. A synthetic ophthalmic device according to claim 1, further comprising a posterior anchoring band.

10. A synthetic ophthalmic device according to claim 1, further comprises at least one opening on a slant surface area of said truncated hemisphere.

11. (canceled)

12. A synthetic ophthalmic device according to claim 1, wherein said porous polymeric structure comprises nanofibers.

13. A synthetic ophthalmic device according to claim 1, wherein said porous polymeric structure comprises at least one porous electrospun polymer.

14. A synthetic ophthalmic device according to claim 1, wherein said porous polymeric structure comprises at least one polymer selected from poly(D carbonate) polycaprolactone (PCL), polylactic acid (PLA), poly-L-lactic acid (PLLA), Poly(DL-lactide-co-caprolactone, Poly (ethylene-co-vinyl acetate) vinyl acetate, Poly(methyl methacrylate), Poly(propylene carbonate), Poly(vinylidene fluoride), Polyacrylonitrile, Polycaprolactone, Polycarbomethylsilane, Polylactic acid, Polystyrene, Polyvinylpyrrolidone, poly vinyl alcohol (PVA), polyethylene oxide (PEO), polyurethane, aromatic polyurethane, polycarbonate, polyvinyl chloride (PVC), hyaluronic acid (HA), chitosan, alginate, polyhydroxybuyrate and its copolymers, Nylon 11, Cellulose acetate, hydroxyappetite, poly(3-hydroxybutyric acid-co-3-hydroxyvaleric acid), poly(DL-lactide), polycaprolactone, and poly(L-lactide) or any combination thereof.

15. A synthetic ophthalmic device according to claim 1, further comprising at least one active agent.

16. (canceled)

17. A synthetic ophthalmic device according to claim 1, wherein said first radius is at least 5 mm.

18. A synthetic ophthalmic device according to claim 1, wherein said first radius is in the range of between about 5 to 15 mm.

19. A synthetic ophthalmic device according to claim 1, wherein said second radius is in the range of between about 7 to 13 mm.

20. A synthetic ophthalmic device according to claim 1, wherein said height between first and second radius is at least 1 mm.

21. A synthetic ophthalmic device according to claim 1, wherein said height between first and second radius is in the range of between about 1 to 10 mm.

22. A method of treatment and/or slowing the progression of myopia and any disease, disorder, condition or symptom associated therewith, said method comprising the step of transplanting into the eye of a subject in need thereof a synthetic ophthalmic device comprising a porous polymeric structure; wherein said structure is in the shape of a truncated hemisphere having a first top circular opening with a first radius and a hemisphere bottom opening with a second radius and a hemisphere height defined between the centers of said first and second openings; and wherein said porous polymer has pores of less than 5 microns.

23. (canceled)

24. A method according to claim 22, wherein said disease, disorder, condition or symptom associate with myopia is selected from Terrien's marginal degeneration, brittle cornea syndrome, Ehlers-Danlos syndrome, osteogenesis imperfecta syndrome, pseudoxanthoma elasticum, congenital cornea plana, scleromalacia perforans, myopia, Rheumatoid arthritis, Marfan syndrome and any combinations thereof; said method comprising the step of transplanting into the eye of a subject in need thereof a synthetic ophthalmic device comprising a porous polymeric structure; wherein said structure is in the shape of a truncated hemisphere having a first top circular opening with a first radius and a hemisphere bottom opening with a second radius and a hemisphere height defined between the centers of said first and second openings; and wherein said porous polymer has pores of less than 5 microns.

Description

BRIEF DESCRIPTION OF THE DRAWINGS

[0043] The subject matter regarded as the invention is particularly pointed out and distinctly claimed in the concluding portion of the specification. The invention, however, both as to organization and method of operation, together with objects, features, and advantages thereof, may best be understood by reference to the following detailed description when read with the accompanying drawings in which:

[0044] FIG. 1 shows an embodiment of a device of the invention.

[0045] It will be appreciated that for simplicity and clarity of illustration, elements shown in the FIGURES have not necessarily been drawn to scale. For example, the dimensions of some of the elements may be exaggerated relative to other elements for clarity. Further, where considered appropriate, reference numerals may be repeated among the FIGURES to indicate corresponding or analogous elements.

DETAILED DESCRIPTION OF THE PRESENT INVENTION

[0046] In the following detailed description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be understood by those skilled in the art that the present invention may be practiced without these specific details. In other instances, well-known methods, procedures, and components have not been described in detail so as not to obscure the present invention.

[0047] FIG. 1 shows an embodiment of a synthetic ophthalmic device of the invention (100). Said device comprises a porous polymeric structure in the shape of a truncated hemisphere (101) having a first top circular opening (102) with a first radius (103) and a hemisphere bottom opening (104) with a second radius (not shown) and a hemisphere height defined between the centers of said first and second openings (not shown); and wherein said porous polymer has pores of less than 5 microns. Said device further comprises two openings (105) on a slant surface area (106) of said truncated hemisphere. Additionally, the device shown in FIG. 1 also comprises a posterior anchoring band (107) having a posterior anchoring surface (108).

[0048] One embodiment can be a truncated hemisphere covering the anterior sclera overlying the insertion of the ciliary body. Rabbit trials will be carried out and compared to a non-operated eye. We expect to see a lesser elongation of the implanted eye thus proving the mechanism of action. Rabbit trials carried out to date prove seamless integration Basing biocompatibility and safety.

[0049] While certain features of the invention have been illustrated and described herein, many modifications, substitutions, changes, and equivalents will now occur to those of ordinary skill in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.